NCT03362112 is a clinical trial in Type2 Diabetes, sponsored by Nanjing First Hospital, Nanjing Medical University.

Who is sponsoring NCT03362112?

NCT03362112 is sponsored by Nanjing First Hospital, Nanjing Medical University.

What condition does NCT03362112 study?

NCT03362112 studies Type2 Diabetes.

Is NCT03362112 still recruiting?

NCT03362112 is currently completed. Last updated 14 April 2022.

Are results published for NCT03362112?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2022-04-14 · How we verify

NCT03362112

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes

Completed Results posted Last updated 14 April 2022

What this trial tests

trial in Type2 Diabetes in 1,713 participants. Completed in 1 June 2017.

Timeline

30 January 2015

Primary endpoint
31 August 2016

1 June 2017

Quick facts

Lead sponsor	Nanjing First Hospital, Nanjing Medical University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,713
Start date	30 January 2015
Primary completion	31 August 2016
Estimated completion	1 June 2017

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Nanjing First Hospital, Nanjing Medical University

Who can join

Eligibility, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Lipoprotein-associated Phospholipase A2 Primary · Day one

the plasma lipoprotein-associated phospholipase A2 level of patients

Group	Value	95% CI
Patients With T2DM	238.4	± 111.9

HbA1c Secondary · Day one

the glycosylated hemoglobin level of patients

Group	Value	95% CI
Patients With T2DM	9.1	± 2.1

LDL-c Secondary · Day one

low density lipoprotein cholesterol

Group	Value	95% CI
Patients With T2DM	2.5	± 0.8

Sponsor's own description

Lipoprotein-associated phospholipase A2 (LP-PLA2) is a good marker of cardiovascular risk and inflammation. This study aims at the characteristic and clinical significance of LP-PLA2 test in patients with type 2 diabetes(T2D).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Lipoprotein-associated phospholipase A2 is a risk factor for diabetic kidney disease.
Hu Y, Li TT, Zhou W, Lu TT, et al · · 2019 · cited 11× · PMID 30904742 · DOI 10.1016/j.diabres.2019.03.026

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Nanjing First Hospital, Nanjing Medical University trials

Trials by the same sponsor.

NCT07349979 — PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy · NA · not yet recruiting
NCT07505056 — Jianpi Lishi Jiedu Granules for Prevention of Postoperative Recurrence in Colorectal Advanced Adenomas · Phase 3 · not yet recruiting
NCT07397234 — Thyroid Cartilage Plane VS Superior Laryngeal Nerve Space Block in Awake Tracheal Intubation · NA · not yet recruiting
NCT07455448 — Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study · completed
NCT07385885 — Ultrasound-guided Non-invasive Simulation in Anesthesia Residency Training · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03362112 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nanjing First Hospital, Nanjing Medical University
Last refreshed: 14 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03362112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing